HUTCHMED (China) (HCM) vs Precigen (PGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Precigen (PGEN) has outperformed HUTCHMED (China) (HCM) over the past year, gaining 127.8% versus a loss of 10.6%. Over five years, PGEN leads with a +62.2% price change compared with -55.8% for HCM. Precigen is the larger company by market cap ($2.73 billion vs $2.37 billion), about 1.2 times the size.
HUTCHMED (China) converts more of its revenue into profit, with a net margin of 83.3% versus -2588.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCM | PGEN |
|---|---|---|
| Share price | $13.63 | $7.62 |
| Market cap | $2.37B | $2.73B |
| 1-day change | -4.54% | +0.99% |
| YTD return | +7.13% | +80.38% |
| 1-year return | -10.64% | +127.79% |
| 5-year return | -55.79% | +62.15% |
| P/E ratio (TTM) | 136.30 | — |
| Forward P/E | 52.58 | — |
| EPS (TTM) | $0.10 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $548.51M | $9.68M |
| Revenue growth (YoY) | -12.96% | +146.73% |
| Net income (latest FY) | $456.91M | $-250.64M |
| Gross margin | 38.68% | — |
| Operating margin | -7.14% | -1141.13% |
| Net margin | 83.30% | -2588.21% |
| 52-week high | $16.33 | $8.98 |
| 52-week low | $9.77 | $2.99 |
| Distance from 52-week high | -16.53% | -15.20% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +61.48% | +79.25% |
| Average volume | 67.70K | 5.02M |
| Shares outstanding | 173.81M | 358.04M |
| Employees | 1,790 | 160 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PGEN has outperformed HCM by 138.4 percentage points over the past year.
- HUTCHMED (China) is more profitable, keeping 83.3 cents of every revenue dollar as net income versus -2588.2 cents for Precigen.
- Precigen grew revenue faster in its latest fiscal year (+146.73% vs -12.96%).
About HUTCHMED (China)
HCM stock →HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,790 employees
About Precigen
PGEN stock →Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 160 employees
HCM vs PGEN FAQ
Which is bigger, HUTCHMED (China) or Precigen?
Precigen (PGEN) is larger, with a market capitalization of $2.73B compared with $2.37B for HUTCHMED (China) (HCM).
Which stock has performed better over the past year, HCM or PGEN?
PGEN returned +127.79% over the past 12 months, compared with -10.64% for HCM (price return, excluding dividends). Past performance does not predict future results.
Are HUTCHMED (China) and Precigen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.